Paysign, Inc. (PAYS)

NASDAQInformation TechnologySpecialty Business ServicesSnapshot 2026-10-23

$14.92-1.91%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Paysign, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$28.5M–$30M	—
EPS	$0.09–$0.1	—
EBITDA	$9.5M–$10Mnon-GAAP	—
Gross margin	61%–63%	—
Revenue growth	32%–38.9%	—
FY 2026 · Q4
Revenue	—	29.35M
EPS	—	0.058
FY 2026 · Annual
Revenue	$114M–$117M	114.66M
EPS	$0.35–$0.37	0.345
EBITDA	$35M–$38Mnon-GAAP	—
Gross margin	62%–63%	—
Revenue growth	39%–43%	—
FY 2027 · Annual
Revenue	—	133.65M
EPS	—	0.425

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross profit rises to about $18.2M in 2026-Q1	Profit margins expand, with gross profit rising from $13.1M to $18.2M in recent quarters.	Intact	Gross profit falls below $15M in next 4 quarters	Gross profit: $17.897M FY2026-Q2; GAAP. Published target: ~$18.2M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 202617,897,023 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 795456f5-9357-409b-983c-dc1d967753d9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of last 2 quarters. Gross profit margin improved from 61.6% in 2025-Q2 to 63.3% in 2026-Q2, and operating margin rose from 7.5% to 24.8% in the same period. Management's focus on mix shift and expense discipline is reflected in these margin expansions, indicating delivery on this operational priority. Delivery assessment Oct 24, 2026
Net income doubles to about $5.4M in 2026-Q1	Net income doubled from $1.4M to $5.4M, showing strong profit growth.	Intact	Net income falls below $3M in next 4 quarters	Net income: $6.757M FY2026-Q2; GAAP. Published target: ~$5.4M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 20266,756,537 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 795456f5-9357-409b-983c-dc1d967753d9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of last 2 quarters. Net income rose from $1.39M in 2025-Q2 to $6.76M in 2026-Q2, a 386.9% increase. Full-year 2026 net income guidance of $13.0M to $16.0M nearly doubles the 2025 expected range of $7.0M to $8.0M. Management is delivering on the goal to double net income over 2025. Delivery assessment Oct 24, 2026
Revenue grows to about $108.5M in FY26	Paysign grows revenue about 23% yearly to $108.5M in 2026.	Intact	Revenue falls below $100M in FY26	Revenue: $28.252M FY2026-Q2; GAAP. Published target: ~$108.5M. Target period is not explicitly aligned with this observation. Source published Aug 6, 202628,252,071 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 795456f5-9357-409b-983c-dc1d967753d9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of last 2 quarters. Pharma revenue grew 88.9% from $7.75M in 2025-Q2 to $14.65M in 2026-Q2, while plasma revenue grew 21.4% from $10.74M to $13.04M in the same period. Management consistently expects plasma and pharma to contribute roughly equally to revenue, delivering on this strategic growth priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	$125,019,800	3 / 5
2026-07-26	Unavailable	$125,019,800	3 / 5
2026-07-27	Unavailable	$125,019,800	3 / 5
2026-07-28	Unavailable	$125,019,800	3 / 5
2026-07-29	Unavailable	Unavailable	2 / 3
2026-07-30	Unavailable	Unavailable	2 / 3
2026-07-31	Unavailable	$125,019,800	3 / 5
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	$125,019,800	3 / 5
2026-08-03	Unavailable	Unavailable	2 / 3
2026-08-04	Unavailable	Unavailable	2 / 3
2026-08-05	Unavailable	$125,019,800	3 / 5
2026-08-06	Unavailable	Unavailable	2 / 3
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	$132,558,000	2 / 5
2026-08-09	Unavailable	$132,558,000	2 / 5
2026-08-10	Unavailable	$132,558,000	2 / 5
2026-08-12	Unavailable	Unavailable	2 / 3
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	2 / 3
2026-09-27	Unavailable	Unavailable	2 / 3
2026-09-28	Unavailable	Unavailable	2 / 3
2026-09-29	Unavailable	Unavailable	2 / 3
2026-09-30	Unavailable	Unavailable	2 / 3
2026-10-01	Unavailable	Unavailable	2 / 3
2026-10-02	Unavailable	Unavailable	2 / 3
2026-10-03	Unavailable	Unavailable	2 / 3
2026-10-04	Unavailable	Unavailable	2 / 3
2026-10-05	Unavailable	Unavailable	2 / 3
2026-10-06	Unavailable	Unavailable	2 / 3
2026-10-07	Unavailable	Unavailable	2 / 3
2026-10-08	Unavailable	Unavailable	2 / 3
2026-10-09	Unavailable	Unavailable	2 / 3
2026-10-10	Unavailable	Unavailable	2 / 3
2026-10-11	Unavailable	Unavailable	2 / 3
2026-10-12	Unavailable	Unavailable	2 / 3
2026-10-13	Unavailable	Unavailable	2 / 3
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	2 / 3
2026-10-17	Unavailable	Unavailable	2 / 3
2026-10-18	Unavailable	Unavailable	2 / 3
2026-10-19	Unavailable	Unavailable	2 / 3
2026-10-20	Unavailable	Unavailable	2 / 3
2026-10-21	Unavailable	Unavailable	2 / 3
2026-10-22	Unavailable	Unavailable	2 / 3
2026-10-23	Unavailable	Unavailable	2 / 3
2026-10-24	Unavailable	Unavailable	2 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

D.A. DavidsonSep 30 · prior Aug 6

$12.00 → $15.00+25.0%

$0$8.25$16.50

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross profit rises to about $18.2M in 2026-Q1Gross profit: $17.897M
Net income doubles to about $5.4M in 2026-Q1Net income: $6.757M
Revenue grows to about $108.5M in FY26Revenue: $28.252M

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-46.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Paysign, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

PAYS is a growth-oriented business, with recent strength in earnings and expanding margins. Management is on track with its stated priorities, but high risk and a recent earnings miss make the thesis less settled than the operating results alone suggest.

What's priced into Paysign, Inc.

The valuation is expensive versus peers, with a 1.21 premium, though the expectations gap is close to neutral and the valuation signal is described as justified. This suggests the market already recognizes much of the recent improvement, without the evidence showing an extreme expectations gap.

What the fundamentals likely do

Over the multi-year view, progress depends on continued growth in both pharma and plasma revenue and on maintaining margin gains. Recent results show strong net income growth and higher operating margins, but a recent earnings miss and a 45% estimated miss probability make the next report a near-term risk.

What Paysign, Inc. hinges on

A key risk is a guidance cut after the recent raise, which could weaken confidence in management's outlook. Favorable conditions include interest-rate cuts and continued earnings strength from sector peers, while the central test remains whether PAYS sustains its revenue growth and execution.